Abstract: A vector comprising a first polynucleotide encoding a FOXP3 polypeptide and a second polynucleotide encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen recognition domain which specifically binds to a human leukocyte antigen (HLA), wherein the first polynucleotide and the second polynucleotide are operably linked to the same promoter, and wherein the first polynucleotide is upstream of the second polynucleotide.

Abstract: TCR The present invention relates to an engineered T cell receptor (TCR). In particular, the present invention relates to methods for expression of a TCR when expressed as an exogenous TCR, to methods for selecting a TCR with high cell surface expression when expressed as an exogenous TCR and to methods for identifying residues which contribute to the cell surface expression level of a TCR. The present invention also relates to an engineered TCR which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Abstract: The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Abstract: A method for increasing the cell surface expression and/or reducing mispairing of a TCR.

Abstract: The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the ? chain; R9 of the ? chain; Y10 of the ? chain; T24 of the ? chain; V19 of the ? chain; T20 of the ? chain; M50 of the ? chain; T5 of the ? chain; Q8 of the ? chain; S86 of the ? chain; F39 of the ? chain; D55 of the ? chain; R43 of the ? chain; A66 of the ? chain; V19 of the ? chain; L21 of the ? chain; L103 of the ? chain; T3 of the ? chain; S7 of the ? chain; P9 of the ? chain; M11 of the ? chain; A16 of the ? chain; T18 of the ? chain; L21 of the ? chain; S22 of the ? chain; D26 of the ? chain; F40 of the ? chain; S47 of the ? chain; R48 of the ? chain; Q49 of the ? chain; 151 of the ? chain; L52 of the ? chain; V53 of the ? chain; T67 of the ? chain; E68 of the ? chain; N74 of the ? chain; F76 of the ? chain; N79 of the ? chain; Q81 of the ? chain; A83 of the ? chain; K90 of the ? chain; S92 of the ? chain; D93 of the ? chain; and M101 of the ? chain; wherein the at

Abstract: The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Abstract: The present invention relates to a method for enhancing the ability of regulatory T cells (Tregs) to suppress immune responses comprising increasing FOXP3 expression in a population of Tregs.

Abstract: TCR The present invention relates to an engineered T cell receptor (TCR). In particular, the present invention relates to methods for expression of a TCR when expressed as an exogenous TCR, to methods for selecting a TCR with high cell surface expression when expressed as an exogenous TCR and to methods for identifying residues which contribute to the cell surface expression level of a TCR. The present invention also relates to an engineered TCR which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: The present invention relates to a natural killer T (NKT) cell comprising an engineered T cell receptor (TCR) which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the ? chain; R9 of the ? chain; Y10 of the ? chain; T24 of the ? chain; V19 of the ? chain; T20 of the ? chain; M50 of the ? chain; T5 of the ? chain; Q8 of the ? chain; S86 of the ? chain; F39 of the ? chain; D55 of the ? chain; R43 of the ? chain; A66 of the ? chain; V19 of the ? chain; L21 of the ? chain; L103 of the ? chain; T3 of the ? chain; S7 of the ? chain; P9 of the ? chain; M11 of the ? chain; A16 of the ? chain; T18 of the ? chain; L21 of the ? chain; S22 of the ? chain; D26 of the ? chain; F40 of the ? chain; S47 of the ? chain; R48 of the ? chain; Q49 of the ? chain; I51 of the ? chain; L52 of the ? chain; V53 of the ? chain; T67 of the ? chain; E68 of the ? chain; N74 of the ? chain; F76 of the ? chain; N79 of the ? chain; Q81 of the ? chain; A83 of the ? chain; K90 of the ? chain; S92 of the ? chain; D93 of the ? chain; and M101 of the ? chain; wherein the at

Abstract: The present invention provides a method for increasing the sensitivity of a T cell expressing a cell-surface antibody to a target antigen, which comprises the step of lowering the affinity of the antibody to the target antigen by at least 100-fold. The invention also provides chimeric antigen receptor comprising an antibody domain having an affinity for antigen in the range 100-1 ?M, its encoding nucleic acid sequence and uses thereof.

Abstract: The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC.

Abstract: The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC.

Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.

Abstract: The present invention provides a method for increasing the sensitivity of a T cell expressing a cell-surface antibody to a target antigen, which comprises the step of lowering the affinity of the antibody to the target antigen by at least 100-fold. The invention also provides chimeric antigen receptor comprising an antibody domain having an affinity for antigen in the range 100-1 ?M, its encoding nucleic acid sequence and uses thereof.

Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from the cytomegalovirus (CMV) phosphoprotein pp65 having the amino acid sequence NLVPMVATV (SEQ ID No. 1) when presented by a major histocompatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a CMV-specific T-cell. The present invention also provides the use of CMV-specific T-cell for cellular immunotherapy.

Abstract: The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC.

Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from the cytomegalovirus (CMV) phosphoprotein pp65 having the amino acid sequence NLVPMVATV (SEQ ID No. 1) when presented by a major histocompatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a CMV-specific T-cell. The present invention also provides the use of CMV-specific T-cell for cellular immunotherapy.

Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.